

Table S4. Median duration of registry follow-up until stop/switch for first-line, second-line, and third-line treatments; patients with psoriatic arthritis initiating new therapy during the registry

	<u>Ustekinumab</u>	<u>Infliximab</u>	<u>Adalimumab</u>	<u>Etanercept</u>	<u>All</u>
First-line therapy starts, N	41	20	33	25	119
Median, Years	1.87	1.39	2.22	2.69	2.22
Second-line therapy starts, N	63	18	84	27	192
Median, Years	2.62	3.14	2.61	2.52	2.73
Third-line therapy starts, N	82	19	22	18	141
Median, Years	2.98	2.89	2.92	3.19	3.00